Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

610 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer.
Aglietta M, Barone C, Sawyer MB, Moore MJ, Miller WH Jr, Bagalà C, Colombi F, Cagnazzo C, Gioeni L, Wang E, Huang B, Fly KD, Leone F. Aglietta M, et al. Among authors: barone c. Ann Oncol. 2014 Sep;25(9):1750-1755. doi: 10.1093/annonc/mdu205. Epub 2014 Jun 6. Ann Oncol. 2014. PMID: 24907635 Free article. Clinical Trial.
Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study.
Pozzo C, Barone C, Szanto J, Padi E, Peschel C, Bükki J, Gorbunova V, Valvere V, Zaluski J, Biakhov M, Zuber E, Jacques C, Bugat R. Pozzo C, et al. Among authors: barone c. Ann Oncol. 2004 Dec;15(12):1773-81. doi: 10.1093/annonc/mdh473. Ann Oncol. 2004. PMID: 15550582 Free article. Clinical Trial.
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
Orlandi A, Calegari MA, Martini M, Cocomazzi A, Bagalà C, Indellicati G, Zurlo V, Basso M, Cassano A, Larocca LM, Barone C. Orlandi A, et al. Among authors: barone c. Clin Transl Oncol. 2016 Oct;18(10):988-95. doi: 10.1007/s12094-015-1471-z. Epub 2016 Jan 7. Clin Transl Oncol. 2016. PMID: 26742940
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.
Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, Wenczl M, Goker E, Cisar L, Wang K, Bugat R. Dank M, et al. Among authors: barone c. Ann Oncol. 2008 Aug;19(8):1450-1457. doi: 10.1093/annonc/mdn166. Epub 2008 Jun 16. Ann Oncol. 2008. PMID: 18558665 Free article. Clinical Trial.
Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone.
Novello S, Bruzzi P, Barone C, Buosi R, Masotti A, Michetti G, Fioretti M, Barbera S, Spatafora M, Garetto L, Mazzanti P, Dongiovanni V, Selvaggi G, Crinò L, Scagliotti GV. Novello S, et al. Among authors: barone c. Ann Oncol. 2007 May;18(5):903-8. doi: 10.1093/annonc/mdm061. Epub 2007 Mar 9. Ann Oncol. 2007. PMID: 17351253 Free article. Clinical Trial.
The immune response to tumors as a tool toward immunotherapy.
Pandolfi F, Cianci R, Pagliari D, Casciano F, Bagalà C, Astone A, Landolfi R, Barone C. Pandolfi F, et al. Among authors: barone c. Clin Dev Immunol. 2011;2011:894704. doi: 10.1155/2011/894704. Epub 2011 Dec 5. Clin Dev Immunol. 2011. PMID: 22190975 Free PMC article. Review.
610 results